

Match Overview

- 1** **Internet** 17 words
crawled on 10-May-2020
www.researchsquare.com <1%
- 2** **Crossref** 16 words
Tsubouchi, Naoko, Hirofumi Uto, Kotaro Kumagai, Fumisato Sasaki, Shuji Kanmura, Masatsugu Numata, Akihiro Moriuchi, <1%

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 59227

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Risk factors for de novo hepatitis B during solid cancer treatment

de novo HBV in solid cancer

Abstract

BACKGROUND

Reactivation of hepatitis B virus (HBV) during anticancer treatment is a critical issue. When treating patients with solid tumors, it is unclear whether specific cancer types or treatments affect HBV reactivation in hepatitis B surface antigen (HBsAg)-negative and hepatitis B core antibody (HBcAb)-positive patients, so-called de novo hepatitis B patients. The risk of de novo hepatitis B may vary based on different background factors.



ALL

IMAGES

VIDEOS

142,000 Results

Any time ▾

Prevalence and risk factors of hepatitis B virus ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/ajco.13050>

Anti-CD20 antibodies and the administration of steroids for hematopoietic tumors are high risk factors for de novo hepatitis B. 1 This condition has even higher rates of fulmination and mortality than normal hepatitis B infection. 2 It is important to perform HBV screening in such patients for the prevention and early diagnosis of de novo hepatitis B.

Cited by: 3

Author: Takeshi Kotake, Hironaga Satake, Yoshih...

Publish Year: 2019

Hepatitis B Virus Reactivation in the Setting of Cancer ...

https://academic.oup.com/cid/article/62/suppl_4/S306/2473976 ▾

May 17, 2016 · Hepatitis B virus reactivation (HBVr) was first described in the mid-1970s in the setting of cancer chemotherapy and kidney transplant. Since that time it has been shown to be a complication of many immunosuppressive drug therapies (ISDTs) that are routinely used across medical specialties for nonmalignant indications.

Cited by: 23

Author: Stevan A. Gonzalez, Robert P. Perrillo

Publish Year: 2016

New Markers in Monitoring the Reactivation of Hepatitis B ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784136>

Hepatitis B virus (HBV) persistence is at the basis of HBV reactivation as a consequence of chemotherapy and immunosuppressive treatments. The identification of early viral replication indicators and markers of effective HBV immunological control would be useful in monitoring patients who are at risk of potential viral reactivation during the course of immunosuppressive treatment.

Cited by: 2

Author: Valentina Svicher, Romina Salpini, Vincen...

Publish Year: 2019

Occult Hepatitis B: Clinical Viewpoint and Management

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603201>

Mar 04, 2013 · Host factors include intensity of immunosuppression especially with rituximab plus steroid and hematopoietic stem cell transplantation, and viral factors include absence of anti-HBs before chemotherapy, decrease in anti-HBs during chemotherapy, detectable HBV DNA in the serum, HBV genotype B, and mutations in the precore and core promoters [51, 52].

Risk factors for de novo hepatitis B during solid cancer treatment



ALL

IMAGES

VIDEOS

70,300 Results

Any time ▾

Prevalence and risk factors of hepatitis B virus ...

<https://onlinelibrary.wiley.com/doi/10.1111/ajco.13050>

Anti-CD20 antibodies and the administration of steroids for hematopoietic tumors are high risk factors for de novo hepatitis B. 1 This condition has even higher rates of fulmination and mortality than normal hepatitis B infection. 2 It is important to perform HBV screening in such patients for the prevention and early diagnosis of de novo hepatitis B.

Cited by: 3

Author: Takeshi Kotake, Hironaga Satake, Yoshihiro...

Publish Year: 2019

[PDF] Prevalence and risk factors of hepatitis B virus ...

<https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.13050>

The frequency and severity of de novo hepatitis B in patients with solid tumors have not been clarified because of the small number of ... DNA during chemotherapy (Table 2). In addition, two other patients ... this is the largest study to evaluate the risk factors in detail of de novo hepatitis B in patients with solid tumors with resolved HBV.

New Markers in Monitoring the Reactivation of Hepatitis B ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784136>

Hepatitis B virus (HBV) persistence is at the basis of HBV reactivation as a consequence of chemotherapy and immunosuppressive treatments. The identification of early viral replication indicators and markers of effective HBV immunological control would be useful in monitoring patients who are at risk of potential viral reactivation during the course of immunosuppressive treatment.

Cited by: 2

Author: Valentina Svicher, Romina Salpini, Vincenz...

Publish Year: 2019



ALL

IMAGES

VIDEOS

MAPS

NEWS

SHOPPING

850,000 Results

Any time ▾

[Prevalence and risk factors of hepatitis B virus ...](#)

<https://onlinelibrary.wiley.com/doi/10.1111/ajco.13050>

Anti-CD20 antibodies and the administration of steroids for hematopoietic tumors are high risk factors for de novo hepatitis B. 1 This condition has even higher rates of fulmination and mortality than normal hepatitis B infection. 2 It is important to perform HBV screening in such patients for the prevention and early diagnosis of de novo hepatitis B.

Cited by: 3 Author: Takeshi Kotake, Hironaga Satake, Yoshihi...

Publish Year: 2019

[\[PDF\] Prevalence and risk factors of hepatitis B virus ...](#)

<https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.13050>

The frequency and severity of de novo hepatitis B in patients with solid tumors have not been clarified because of the small number of ... DNA during chemotherapy (Table 2). In addition, two other patients ... this is the largest study to evaluate the risk factors in detail of de novo hepatitis B in patients with solid tumors with resolved HBV.

[Hepatitis B Reactivation During Cancer Chemotherapy: An ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833504>

Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000; 62:299–307.

Cited by: 51 Author: Jessica P. Hwang, Andrea G. Barbo, Rob...

Publish Year: 2015

PEOPLE ALSO ASK

What is the treatment for acute hepatitis B? ▾

What is hepatitis B surface antigen? ▾

What is the incubation period of hepatitis B? ▾